Smith & Nephew recently announced the first surgical case of its robotics-assisted total knee replacement procedure. The new approach, which recently received 510(k) clearance from the FDA, uses the Navio Surgical System to implant the Journey II BCS and CR total knee systems.
The surgery was performed by Dr. Brian McGinley at the John T. Mather Memorial Hospital in Port Jefferson, NY. Dr. McGinley notes, “The handheld robotics-assisted Navio platform provided me a precise and efficient placement of the Journey II BCS. I was delighted to see how seamlessly it integrated into our workflow.”
During a total knee replacement surgery, the Navio system is designed to deliver consistent and accurate results through the utilization of a robotics-assisted hand piece, navigation, and Navio-specific cut guides, all of which enable better patient outcomes. The Navio intra-operative planning software uses 3D surface capture to predict joint laxity, enable precise implant positioning, and customize a solution for each patient. Unlike other robotics-assisted platforms, the Navio system does not require a pre-operative CT scan.
While Smith & Nephew’s Journey PFJ, Journey UNI, Stride and ZUK partial knee systems have been widely available for use with the NAVIO system, this milestone marks the first time orthopaedic surgeons have access to the robotics-assisted technology when implanting the company’s total knee systems. Currently available for the Journey II total knee system, additional total knee systems are expected to be supported by the Navio system in future releases.
“We’re excited to introduce the combination of our Navio Surgical System and the Journey II total knee system to the orthopaedic community,” says Mike Donoghue, Senior Vice President of Global Marketing for Orthopaedics at Smith & Nephew. “Surgeons now have access to a highly portable, robotics-assisted technique that marks the next step in Smith & Nephew’s pioneering approach to joint reconstruction. This cost-effective procedure positions us particularly well in the U.S. market, where bundled payments and ambulatory surgery centers have shifted focus to the economic feasibility and overall value of new technology for joint replacement procedures.”
